Merck's Deck Marked: Agrees to $58 Million Settlement
                   
pharmiweb.co.uk: Merck’s Deck Marked: Agrees to $58 Million Settlement pharmiweb.co.uk
pharmiweb.co.uk
21-May-2008 175 related
        

by Daisy Sarma - 0 comments Even while admitting to no wrong practices and defending the way it marketed Vioxx, one of its popular painkillers at one point in time, Merck and Co. has agreed to shell out $58 million as part of a settlement against lawsuits that alleged, the advertisements put out... [read full story]                    

Add Comment
There are also 175 related articles
View all news articles about*:
Analgesics Anti-inflammatory Corporate Crime Issues Judiciary Lawsuits Legal Medication Medicines Pharmaceuticals Remedies
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies

View other selected articles:

                   

Respiratory Problems - Lungs (General)

londondivingchamber.co.uk
1 mins ago
        

I am keen to take up scuba but my medical background do not seems like allow me to do so.I am on medication of Theophylline SR 250mg twice a day andsometimes smoke 2-5 sticks of cigarette a day. Frequently, i do swimmingonce or...

add comment
                   

US Food and Drug Administration: FDA Approves New Drug to Treat Severe Form of Epilepsy

pharmiweb.co.uk
19 mins ago 8 related
        

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome. "This approval offers another treatment...

add comment

Azur Pharma and Elan Corporation NYSE: ELN Sign Agreement to Develop a Once-Daily Clozapine

pharmiweb.co.uk
19 mins ago
        

Azur Pharma Limited ("Azur") announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc's ("Elan")(NYSE:ELN) proprietary drug delivery...

add comment
                   
themoneytimes.com: London -- A British study suggests pregnant women exposed to hairspray at work are twice as likely to have a son with the genital birth defect hypospadias. themoneytimes.com

Hairspray exposure may increase birth defect risk

guardian.co.uk
27 mins ago 23 related
        

Scientists have found preliminary evidence that exposure to hairspray during the first three months of pregnancy increases the risk of a common genetic deformity in baby boys. The team found that the risk of hypospadias - a...

add comment